Coya Therapeutics (COYA) to Release Quarterly Earnings on Tuesday

Coya Therapeutics (NASDAQ:COYA) is projected to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $1.9250 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 9:30 AM ET.

Coya Therapeutics Stock Up 1.0%

COYA stock opened at $4.84 on Tuesday. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $7.75. The company has a market cap of $101.25 million, a P/E ratio of -4.36 and a beta of 0.23. The business’s fifty day moving average is $4.84 and its 200-day moving average is $5.64.

Hedge Funds Weigh In On Coya Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Alyeska Investment Group L.P. bought a new stake in Coya Therapeutics during the 4th quarter worth approximately $4,640,000. AWM Investment Company Inc. bought a new position in Coya Therapeutics in the fourth quarter valued at approximately $4,205,000. Private Management Group Inc. bought a new position in Coya Therapeutics in the fourth quarter valued at approximately $1,626,000. Marshall Wace LLP boosted its holdings in shares of Coya Therapeutics by 438.8% in the fourth quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock valued at $1,307,000 after buying an additional 183,533 shares during the period. Finally, Dauntless Investment Group LLC boosted its holdings in shares of Coya Therapeutics by 199.5% in the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after buying an additional 101,932 shares during the period. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on COYA. BTIG Research raised their target price on Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, February 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, January 8th. Finally, Wall Street Zen upgraded shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $16.00.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.